Bruton's tyrosine kinase: From X-linked agammaglobulinemia toward targeted therapy for B-cell malignancies

Journal of Clinical Oncology

Volumn 32, Issue 17, 2014, Pages 1830-1839

  Ponader, Sabine ^a   Burger, Jan A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE RECEPTOR; BRUTON TYROSINE KINASE; BRUTON TYROSINE KINASE INHIBITOR;

ARTICLE; AUTOIMMUNE DISEASE; AUTOPHOSPHORYLATION; B CELL LEUKEMIA; B LYMPHOCYTE; BIOCHEMISTRY; BURKITT LYMPHOMA; CANCER MORTALITY; DRUG DEVELOPMENT; DRUG EFFICACY; GENE MUTATION; GENETICS; HEMATOPOIETIC CELL; HUMAN; INFLAMMATION; LARGE CELL LYMPHOMA; LEUKEMOGENESIS; LYMPHADENOPATHY; LYMPHOCYTE FUNCTION; LYMPHOCYTOMA; LYMPHOCYTOSIS; MALIGNANT NEOPLASTIC DISEASE; MOLECULARLY TARGETED THERAPY; MULTIPLE MYELOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; X LINKED AGAMMAGLOBULINEMIA;

AGAMMAGLOBULINEMIA; ANIMALS; B-LYMPHOCYTES; GENETIC DISEASES, X-LINKED; HUMANS; LEUKEMIA, B-CELL; LYMPHOMA, B-CELL; MUTATION; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES;

EID: 84905842096     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.53.1046     Document Type: Article

References (112)

1. Bruton OC: Agammaglobulinemia. Pediatrics 9:722-728, 1952
2. Bruton OC, Apt L, Gitlin D, et al: Absence of serum gamma globulins. AMA Am J Dis Child 84:632-636, 1952
3. Buckley RH: Primary immunodeficiency diseases due to defects in lymphocytes. N Engl J Med 343:1313-1324, 2000
4. Janeway CA Jr: How the immune system works to protect the host from infection: A personal view. Proc Natl Acad Sci U S A 98:7461-7468, 2001
5. Khan WN: Colonel Bruton's kinase defined the molecular basis of X-linked agammaglobulinemia, the first primary immunodeficiency. J Immunol 188:2933-2935, 2012
6. Smith CI, Notarangelo LD: Molecular basis for X-linked immunodeficiencies. Adv Genet 35:57-115, 1997
7. Vetrie D, Vorechovský I, Sideras P, et al: The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases. Nature 361:226-233, 1993 (Pubitemid 23034471)
8. Tsukada S, Saffran DC, Rawlings DJ, et al: Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia. Cell 72:279-290, 1993 (Pubitemid 23044942)
9. Honigberg LA, Smith AM, Sirisawad M, et al: The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci U S A 107:13075-13080, 2010
10. Advani RH, Buggy JJ, Sharman JP, et al: Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol 31:88-94, 2013
11. Byrd JC, Furman RR, Coutre SE, et al: Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 369:32-42, 2013
12. Wang ML, Rule S, Martin P, et al: Targeting BTK with ibrutinib in relapsed or refractory mantlecell lymphoma. N Engl J Med 369:507-516, 2013
13. Guioli S, Arveiler B, Bardoni B, et al: Close linkage of probe p212 (DXS178) to X-linked agammaglobulinemia. Hum Genet 84:19-21, 1989 (Pubitemid 20022418)
14. Kwan SP, Terwilliger J, Parmley R, et al: Identification of a closely linked DNA marker, DXS178, to further refine the X-linked agammaglobulinemia locus. Genomics 6:238-242, 1990 (Pubitemid 20164191)
15. Väliaho J, Smith CI, Vihinen M: BTKbase: The mutation database for X-linked agammaglobulinemia. Hum Mutat 27:1209-1217, 2006 (Pubitemid 44749723)
16. Hashimoto S, Tsukada S, Matsushita M, et al: Identification of Bruton's tyrosine kinase (Btk) gene mutations and characterization of the derived proteins in 35 X-linked agammaglobulinemia families: A nationwide study of Btk deficiency in Japan. Blood 88:561-573, 1996 (Pubitemid 26240388)
17. Holinski-Feder E, Weiss M, Brandau O, et al: Mutation screening of the BTK gene in 56 families with X-linked agammaglobulinemia (XLA): 47 unique mutations without correlation to clinical course. Pediatrics 101:276-284, 1998 (Pubitemid 28076664)
18. Conley ME, Dobbs AK, Farmer DM, et al: Primary B cell immunodeficiencies: Comparisons and contrasts. Annu Rev Immunol 27:199-227, 2009
19. Kerns HM, Ryu BY, Stirling BV, et al: B cell-specific lentiviral gene therapy leads to sustained B-cell functional recovery in a murine model of X-linked agammaglobulinemia. Blood 115:2146-2155, 2010
20. Ng YY, Baert MR, Pike-Overzet K, et al: Correction of B-cell development in Btk-deficient mice using lentiviral vectors with codon-optimized human BTK. Leukemia 24:1617-1630, 2010
21. Kohn DB: Update on gene therapy for immunodeficiencies. Clin Immunol 135:247-254, 2010
22. Rawlings DJ, Saffran DC, Tsukada S, et al: Mutation of unique region of Bruton's tyrosine kinase in immunodeficient XID mice. Science 261: 358-361, 1993 (Pubitemid 23281007)
23. Thomas JD, Sideras P, Smith CI, et al: Colocalization of X-linked agammaglobulinemia and X-linked immunodeficiency genes. Science 261:355-358, 1993 (Pubitemid 23281006)
24. Hendriks RW, de Bruijn MF, Maas A, et al: Inactivation of Btk by insertion of lacZ reveals defects in B cell development only past the pre-B cell stage. Embo J 15:4862-4872, 1996 (Pubitemid 26315797)
25. Kerner JD, Appleby MW, Mohr RN, et al: Impaired expansion of mouse B cell progenitors lacking Btk. Immunity 3:301-312, 1995
26. Khan WN, Alt FW, Gerstein RM, et al: Defective B cell development and function in Btkdeficient mice. Immunity 3:283-299, 1995
27. Smith CI, Islam TC, Mattsson PT, et al: The Tec family of cytoplasmic tyrosine kinases: Mammalian Btk, Bmx, Itk, Tec, Txk and homologs in other species. Bioessays 23:436-446, 2001 (Pubitemid 32453973)
28. Berg LJ, Finkelstein LD, Lucas JA, et al: Tec family kinases in T lymphocyte development and function. Annu Rev Immunol 23:549-600, 2005 (Pubitemid 40563180)
29. Mattsson PT, Vihinen M, Smith CI: X-linked agammaglobulinemia (XLA): A genetic tyrosine kinase (Btk) disease. Bioessays 18:825-834, 1996 (Pubitemid 26381054)
30. Mohamed AJ, Yu L, Bäckesjö CM, et al: Bruton's tyrosine kinase (Btk): Function, regulation, and transformation with special emphasis on the PH domain. Immunol Rev 228:58-73, 2009
31. Hyvönen M, Saraste M: Structure of the PH domain and Btk motif from Bruton's tyrosine kinase: Molecular explanations for X-linked agammaglobulinaemia. EMBO J 16:3396-3404, 1997 (Pubitemid 27250035)
32. Mohamed AJ, Nore BF, Christensson B, et al: Signalling of Bruton's tyrosine kinase, Btk. Scand J Immunol 49:113-118, 1999 (Pubitemid 29096305)
33. Dinh M, Grunberger D, Ho H, et al: Activation mechanism and steady state kinetics of Bruton's tyrosine kinase. J Biol Chem 282:8768-8776, 2007 (Pubitemid 47093523)
34. Marcotte DJ, Liu YT, Arduini RM, et al: Structures of human Bruton's tyrosine kinase in active and inactive conformations suggest a mechanism of activation for TEC family kinases. Protein Sci 19:429-439, 2010
35. Vihinen M, Mattsson PT, Smith CI: Bruton tyrosine kinase (BTK) in X-linked agammaglobulinemia (XLA). Front Biosci 5:D917-D928, 2000
36. Lindvall JM, Blomberg KE, Väliaho J, et al: Bruton's tyrosine kinase: Cell biology, sequence conservation, mutation spectrum, siRNA modifications, and expression profiling. Immunol Rev 203:200-215, 2005 (Pubitemid 40185385)
37. Ponader S, Chen SS, Buggy JJ, et al: The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood 119:1182-1189, 2012
38. Burger JA, Montserrat E: Coming full circle: 70 years of chronic lymphocytic leukemia cell redistribution, from glucocorticoids to inhibitors of B-cell receptor signaling. Blood 121:1501-1509, 2013
39. Aoki Y, Isselbacher KJ, Pillai S: Bruton tyrosine kinase is tyrosine phosphorylated and activated in pre-B lymphocytes and receptor-ligated B cells. Proc Natl Acad Sci U S A 91:10606-10609, 1994 (Pubitemid 24329047)
40. de Weers M, Brouns GS, Hinshelwood S, et al: B-cell antigen receptor stimulation activates the human Bruton's tyrosine kinase, which is deficient in X-linked agammaglobulinemia. J Biol Chem 269:23857-23860, 1994 (Pubitemid 24300906)
41. Anderson JS, Teutsch M, Dong Z, et al: An essential role for Bruton's [corrected] tyrosine kinase in the regulation of B-cell apoptosis. Proc Natl Acad Sci U S A 93:10966-10971, 1996
42. Solvason N, Wu WW, Kabra N, et al: Transgene expression of bcl-xL permits anti-immunoglobulin (Ig)-induced proliferation in xid B cells. J Exp Med 187:1081-1091, 1998 (Pubitemid 28176408)
43. Harwood NE, Batista FD: Early events in B cell activation. Annu Rev Immunol 28:185-210, 2010
44. Kurosaki T, Hikida M: Tyrosine kinases and their substrates in B lymphocytes. Immunol Rev 228:132-148, 2009
45. Takesono A, Finkelstein LD, Schwartzberg PL: Beyond calcium: New signaling pathways for Tec family kinases. J Cell Sci 115:3039-3048, 2002
46. Petro JB, Rahman SM, Ballard DW, et al: Bruton's tyrosine kinase is required for activation of IkappaB kinase and nuclear factor kappaB in response to B cell receptor engagement. J Exp Med 191:1745-1754, 2000
47. Bajpai UD, Zhang K, Teutsch M, et al: Bruton's tyrosine kinase links the B cell receptor to nuclear factor kappaB activation. J Exp Med 191:1735-1744, 2000 (Pubitemid 30331570)
48. Lee KG, Xu S, Wong ET, et al: Bruton's tyrosine kinase separately regulates NFkappaB p65RelA activation and cytokine interleukin (IL)-10/IL-12 production in TLR9-stimulated B Cells. J Biol Chem 283:11189-11198, 2008
49. Su TT, Rawlings DJ: Transitional B lymphocyte subsets operate as distinct checkpoints in murine splenic B cell development. J Immunol 168: 2101-2110, 2002 (Pubitemid 34171808)
50. Kil LP, de Bruijn MJ, van Nimwegen M, et al: Btk levels set the threshold for B-cell activation and negative selection of autoreactive B cells in mice. Blood 119:3744-3756, 2012
51. Satterthwaite A, Witte O: Genetic analysis of tyrosine kinase function in B cell development. Annu Rev Immunol 14:131-154, 1996 (Pubitemid 26130180)
52. Jiang Y, Ma W, Wan Y, et al: The G protein G alpha12 stimulates Bruton's tyrosine kinase and a rasGAP through a conserved PH/BM domain. Nature 395:808-813, 1998
53. de Gorter DJ, Beuling EA, Kersseboom R, et al: Bruton's tyrosine kinase and phospholipase Cgamma2 mediate chemokine-controlled B cell migration and homing. Immunity 26:93-104, 2007
54. Liu X, Zhan Z, Li D, et al: Intracellular MHC class II molecules promote TLR-triggered innate immune responses by maintaining activation of the kinase Btk. Nat Immunol 12:416-424, 2011
55. Kubo T, Uchida Y, Watanabe Y, et al: Augmented TLR9-induced Btk activation in PIR-B-deficient B-1 cells provokes excessive autoantibody production and autoimmunity. J Exp Med 206:1971-1982, 2009
56. Chang BY, Francesco M, De Rooij MF, et al: Egress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients. Blood 122:2412-2424, 2013
57. Spaargaren M, Beuling EA, Rurup ML, et al: The B cell antigen receptor controls integrin activity through Btk and PLCgamma2. J Exp Med 198:1539-1550, 2003 (Pubitemid 37467168)
58. Smith CI, Baskin B, Humire-Greiff P, et al: Expression of Bruton's agammaglobulinemia tyrosine kinase gene, BTK, is selectively down-regulated in T lymphocytes and plasma cells. J Immunol 152:557-565, 1994 (Pubitemid 24072959)
59. Genevier HC, Hinshelwood S, Gaspar HB, et al: Expression of Bruton's tyrosine kinase protein within the B cell lineage. Eur J Immunol 24:3100-3105, 1994
60. Jongstra-Bilen J, Puig Cano A, Hasija M, et al: Dual functions of Bruton's tyrosine kinase and Tec kinase during Fcgamma receptor-induced signaling and phagocytosis. J Immunol 181:288-298, 2008
61. Melcher M, Unger B, Schmidt U, et al: Essential roles for the Tec family kinases Tec and Btk in M-CSF receptor signaling pathways that regulate macrophage survival. J Immunol 180:8048-8056, 2008
62. Shinohara M, Koga T, Okamoto K, et al: Tyrosine kinases Btk and Tec regulate osteoclast differentiation by linking RANK and ITAM signals. Cell 132:794-806, 2008 (Pubitemid 351312796)
63. Liu J, Fitzgerald ME, Berndt MC, et al: Bruton tyrosine kinase is essential for botrocetin/VWF-induced signaling and GPIb-dependent thrombus formation in vivo. Blood 108:2596-2603, 2006
64. Quek LS, Bolen J, Watson SP: A role for Bruton's tyrosine kinase (Btk) in platelet activation by collagen. Curr Biol 8:1137-1140, 1998 (Pubitemid 28501379)
65. Jackson SP, Cranmer S, Mangin P, et al: Are Erk, Btk, and PECAM-1 major players in GPIb signaling? The challenge of unraveling signaling events downstream of platelet GPIb. Blood 109:846-847, 2007 (Pubitemid 46105994)
66. Farooqui M, Lozier JN, Valdez J, et al: Ibrutinib (PCI 32765) rapidly improves platelet counts in chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL/SLL) patients and has minimal effects on platelet aggregation. Blood 120, 2012 (abstr 1789)
67. Doyle SL, Jefferies CA, O'Neill LA: Bruton's tyrosine kinase is involved in p65-mediated transactivation and phosphorylation of p65 on serine 536 during NFkappaB activation by lipopolysaccharide. J Biol Chem 280:23496-23501, 2005 (Pubitemid 40884827)
68. Gray P, Dunne A, Brikos C, et al: MyD88 adapter-like (Mal) is phosphorylated by Bruton's tyrosine kinase during TLR2 and TLR4 signal transduction. J Biol Chem 281:10489-10495, 2006 (Pubitemid 43864588)
69. Jefferies CA, Doyle S, Brunner C, et al: Bruton's tyrosine kinase is a Toll/interleukin-1 receptor domain-binding protein that participates in nuclear factor kappaB activation by Toll-like receptor 4. J Biol Chem 278:26258-26264, 2003 (Pubitemid 36835395)
70. Mansell A, Smith R, Doyle SL, et al: Suppressor of cytokine signaling 1 negatively regulates Toll-like receptor signaling by mediating Mal degradation. Nat Immunol 7:148-155, 2006
71. Hasan M, Lopez-Herrera G, Blomberg KE, et al: Defective Toll-like receptor 9-mediated cytokine production in B cells from Bruton's tyrosine kinase-deficient mice. Immunology 123:239-249, 2008
72. Pan Z, Scheerens H, Li SJ, et al: Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase. ChemMedChem 2:58-61, 2007
73. Di Paolo JA, Huang T, Balazs M, et al: Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis. Nat Chem Biol 7:41-50, 2011
74. Chang BY, Huang MM, Francesco M, et al: The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells. Arthritis Res Ther 13:R115, 2011
75. Hutcheson J, Vanarsa K, Bashmakov A, et al: Modulating proximal cell signaling by targeting Btk ameliorates humoral autoimmunity and end-organ disease in murine lupus. Arthritis Res Ther 14:R243, 2012
76. Davis RE, Ngo VN, Lenz G, et al: Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 463:88-92, 2010
77. de Rooij MF, Kuil A, Geest CR, et al: The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. Blood 119:2590-2594, 2012
78. Schmitz R, Young RM, Ceribelli M, et al: Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature 490:116-120, 2012
79. Bröker BM, Klajman A, Youinou P, et al: Chronic lymphocytic leukemic (CLL) cells secrete multispecific autoantibodies. J Autoimmun 1:469-481, 1988
80. Sthoeger ZM, Wakai M, Tse DB, et al: Production of autoantibodies by CD5-expressing B lymphocytes from patients with chronic lymphocytic leukemia. J Exp Med 169:255-268, 1989 (Pubitemid 19035555)
81. Borche L, Lim A, Binet JL, et al: Evidence that chronic lymphocytic leukemia B lymphocytes are frequently committed to production of natural autoantibodies. Blood 76:562-569, 1990 (Pubitemid 20251824)
82. Hervé M, Xu K, Ng YS, et al: Unmutated and mutated chronic lymphocytic leukemias derive from self-reactive B cell precursors despite expressing different antibody reactivity. J Clin Invest 115:1636-1643, 2005 (Pubitemid 40814672)
83. Lanemo Myhrinder A, Hellqvist E, Sidorova E, et al: A new perspective: Molecular motifs on oxidized LDL, apoptotic cells, and bacteria are targets for chronic lymphocytic leukemia antibodies. Blood 111:3838-3848, 2008
84. Chu CC, Catera R, Hatzi K, et al: Chronic lymphocytic leukemia antibodies with a common stereotypic rearrangement recognize nonmuscle myosin heavy chain IIA. Blood 112:5122-5129, 2008
85. Binder M, Léchenne B, Ummanni R, et al: Stereotypical chronic lymphocytic leukemia B-cell receptors recognize survival promoting antigens on stromal cells. PLoS One 5:e15992, 2010
86. Krysov S, Potter KN, Mockridge CI, et al: Surface IgM of CLL cells displays unusual glycans indicative of engagement of antigen in vivo. Blood 115:4198-4205, 2010
87. Kostareli E, Gounari M, Janus A, et al: Antigen receptor stereotypy across B-cell lymphoproliferations: The case of IGHV4-59/IGKV3-20 receptors with rheumatoid factor activity. Leukemia 26:1127-1131, 2012
88. Hoogeboom R, van Kessel KP, Hochstenbach F, et al: A mutated B cell chronic lymphocytic leukemia subset that recognizes and responds to fungi. J Exp Med 210:59-70, 2013
89. Dühren-von Minden M, Übelhart R, Schneider D, et al: Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling. Nature 489:309-312, 2012
90. Binder M, Müller F, Frick M, et al: CLL B-cell receptors can recognize themselves: Alternative epitopes and structural clues for autostimulatory mechanisms in CLL. Blood 121:239-241, 2013
91. Rodríguez A, Martínez N, Camacho FI, et al: Variability in the degree of expression of phosphorylated IkappaBalpha in chronic lymphocytic leukemia cases with nodal involvement. Clin Cancer Res 10:6796-6806, 2004 (Pubitemid 39383028)
92. Herman SE, Gordon AL, Hertlein E, et al: Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood 117:6287-6296, 2011
93. Kil LP, de Bruijn MJ, van Hulst JA, et al: Bruton's tyrosine kinase mediated signaling enhances leukemogenesis in a mouse model for chronic lymphocytic leukemia. Am J Blood Res 3:71-83, 2013
94. Tai YT, Chang BY, Kong SY, et al: Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma. Blood 120:1877-1887, 2012
95. Yang Y, Shaffer AL 3rd, Emre NC, et al: Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. Cancer Cell 21:723-737, 2012
96. Katz FE, Lovering RC, Bradley LA, et al: Expression of the X-linked agammaglobulinemia gene, btk in B-cell acute lymphoblastic leukemia. Leukemia 8:574-577, 1994 (Pubitemid 24133023)
97. Feldhahn N, Río P, Soh BN, et al: Deficiency of Bruton's tyrosine kinase in B cell precursor leukemia cells. Proc Natl Acad Sci U S A 102:13266-13271, 2005 (Pubitemid 41325012)
98. Feldhahn N, Klein F, Mooster JL, et al: Mimicry of a constitutively active pre-B cell receptor in acute lymphoblastic leukemia cells. J Exp Med 201:1837-1852, 2005 (Pubitemid 41002902)
99. Kersseboom R, Middendorp S, Dingjan GM, et al: Bruton's tyrosine kinase cooperates with the B cell linker protein SLP-65 as a tumor suppressor in Pre-B cells. J Exp Med 198:91-98, 2003 (Pubitemid 36870189)
100. Middendorp S, Zijlstra AJ, Kersseboom R, et al: Tumor suppressor function of Bruton tyrosine kinase is independent of its catalytic activity. Blood 105:259-265, 2005 (Pubitemid 40053091)
101. Bäckesjö CM, Vargas L, Superti-Furga G, et al: Phosphorylation of Bruton's tyrosine kinase by c-Abl. Biochem Biophys Res Commun 299:510-515, 2002 (Pubitemid 35365660)
102. MacPartlin M, Smith AM, Druker BJ, et al: Bruton's tyrosine kinase is not essential for Bcr-Abl-mediated transformation of lymphoid or myeloid cells. Leukemia 22:1354-1360, 2008
103. Pan Z: Bruton's tyrosine kinase as a drug discovery target. Drug News Perspect 21:357-362, 2008
104. Uckun FM, Mao C: Tyrosine kinases as new molecular targets in treatment of inflammatory disorders and leukemia. Curr Pharm Des 10:1083-1091, 2004 (Pubitemid 38425893)
105. Singh J, Petter RC, Kluge AF: Targeted covalent drugs of the kinase family. Curr Opin Chem Biol 14:475-480, 2010
106. Mahajan S, Ghosh S, Sudbeck EA, et al: Rational design and synthesis of a novel antileukemic agent targeting Bruton's tyrosine kinase (BTK), LFM-A13 [alpha-cyano-beta-hydroxy-beta-methyl-N-(2,5-dibromophenyl)propenamide]. J Biol Chem 274:9587-9599, 1999
107. Uckun FM, Tibbles H, Venkatachalam T, et al: Preclinical toxicity and pharmacokinetics of the Bruton's tyrosine kinase-targeting anti-leukemic drug candidate, alpha-cyano-beta-hydroxy-beta-methyl-N-(2,5-dibromophenyl) propenamide (LFM-A13). Arzneimittelforschung 57:31-46, 2007 (Pubitemid 46212986)
108. Burger JA, Buggy JJ: Emerging drug profiles: Bruton tyrosine kinase (BTK) inhibitor ibrutinib (PCI-32765). Leuk Lymphoma 54:2385-2391, 2013
109. Dubovsky JA, Beckwith KA, Natarajan G, et al: Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood 122:2539-2549, 2013
110. Cheson BD, Byrd JC, Rai KR, et al: Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia. J Clin Oncol 30:2820-2822, 2012
111. Chang BY, Furman RR, Zapatka M, et al: Use of tumor genomic profiling to reveal mechanisms of resistance to the BTK inhibitor ibrutinib in chronic lymphocytic leukemia (CLL). J Clin Oncol 31:428s, 2013 (suppl 15s; abstr 7014)
112. Evans EK, Tester R, Aslanian S, et al: Inhibition of Btk with CC-292 provides early pharmacodynamic assessment of activity in mice and humans. J Pharmacol Exp Ther 346:219-228, 2013